Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 7,065 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urological Disease Clear all
Completed Phase 2 Interventional Results available

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

NCT02579811
View directory record Official record
Conditions
Metastatic Renal Cell Cancer
Interventions
Axitinib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Duarte, California • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 24, 2026, 5:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Elecoglipron, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
119
States / cities
Huntsville, Alabama • Montgomery, Alabama • Sheffield, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

NCT01282463
View directory record Official record
Conditions
Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
Interventions
Docetaxel, Ramucirumab DP, Icrucumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 24, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

NCT06733363
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Carcinoma, Recurrent Bladder Carcinoma, Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 1 Bladder Cancer AJCC v8
Interventions
Behavioral Dietary Intervention, Telephone- Based Intervention
Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

NCT05620784
View directory record Official record
Conditions
BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge
Interventions
Furosemide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

NCT02966028
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease, ESRD, Coronary Artery Calcification
Interventions
SNF472, Placebo
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
46
States / cities
Bakersfield, California • Chula Vista, California • Escondido, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 24, 2026, 5:14 PM EDT
Terminated Not applicable Interventional Results available

Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract Infection

NCT02198833
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Urine Culture, Foley Catheter Tip Culture, Scanning Electron Microscopy, Device Specific Adverse Event Assessment, Foley Catheter Insertion
Biological · Device · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 1Phase 2 Interventional

Transplant and Addiction Project (TAP) - 1

NCT00249652
View directory record Official record
Conditions
End Stage Liver Disease, End Stage Renal Disease, Substance-Related Disorders
Interventions
TAP, TAU
Behavioral · Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
New York, New York • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Ischemic Preconditioning to Prevent Acute Kidney Injury

NCT02167152
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Ischemic preconditionin
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 24, 2026, 5:14 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

NCT03918447
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, ADPKD
Interventions
Bardoxolone methyl oral capsule, Placebo oral capsule
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 70 Years
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
83
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

NCT01356849
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
59
States / cities
Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 24, 2026, 5:14 PM EDT
Recruiting No phase listed Observational

Partners Calciphylaxis Biobank

NCT03032835
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy, End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Overactive Bladder Telemedicine Non-inferiority Trial

NCT05117918
View directory record Official record
Conditions
Overactive Bladder
Interventions
SUFU Clinical Care Pathway for Overactive Bladder, Telemedicine
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 24, 2026, 5:14 PM EDT
Terminated Not applicable Interventional Results available

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

NCT00147238
View directory record Official record
Conditions
Bladder Cancer, Genitourinary Cancer, Prostate Cancer
Interventions
Ferumoxtran-10 (USPIO), MR lymphangiography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 24, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional

Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

NCT00497926
View directory record Official record
Conditions
Kidney Failure
Interventions
Enriched Hematopoietic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 24, 2026, 5:14 PM EDT
Enrolling by invitation No phase listed Observational

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric AKI

NCT03541785
View directory record Official record
Conditions
Acute Kidney Injury, Renal Replacement Therapy, Pediatric Intensive Care Units
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months to 25 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

NCT03284385
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Adavosertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Orange, California • Sacramento, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

NCT04969315
View directory record Official record
Conditions
Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
Interventions
TT-10, TT-4
Drug
Lead sponsor
Portage Biotech
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Completed No phase listed Observational

Host Response to Pessaries in Microbial Communities of the Postmenopausal Vagina

NCT02605135
View directory record Official record
Conditions
Stress Urinary Incontinence, Prolapse
Interventions
Continued Pessary Use
Device
Lead sponsor
Loyola University
Other
Eligibility
51 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01906489
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 82 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Results available

Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease

NCT02937350
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
D6-25-hydroxyvitamin D3
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 24, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

Nicotinamide Mononucleotide in Patients Undergoing Cardiac Surgery

NCT07013591
View directory record Official record
Conditions
Cardiac Surgery
Interventions
MIB-626, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

NCT05777174
View directory record Official record
Conditions
Kidney Diseases, Kidney Injury, Kidney Failure
Interventions
MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 24, 2026, 5:14 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy

NCT01560091
View directory record Official record
Conditions
Kidney Stones
Interventions
silodosin, Extra-corporeal shock wave lithotripsy, Tamsulosin
Drug · Procedure
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 24, 2026, 5:14 PM EDT